884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

BACKGROUND: Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled Week 48 data from pivotal Phase 3 trials demonstrated noninferiority of CAB LA + RPV LA vs. current antiretroviral regimen (CAR) on the...

Descripción completa

Detalles Bibliográficos
Autores principales: Teichner, Paula, Cutrell, Amy, D’Amico, Ronald, Dorey, David, Griffith, Sandy, Harrington, Conn M, Huang, Jenny, Hudson, Krischan J, Margolis, David, Mrus, Joseph, Polli, Joseph, Spreen, William, Williams, Peter, Van Solingen-Ristea, Rodica, Shaefer, Mark S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809202/
http://dx.doi.org/10.1093/ofid/ofz359.043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809202/
http://dx.doi.org/10.1093/ofid/ofz359.043

Ejemplares similares